よむ、つかう、まなぶ。
資料4 Ⅳ-112,140_メトトレキサート［1.5MB］ (32 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00045.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第67回 2／6）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
（公知申請への該当性に係る企業見解の様式）
要望番号；IV-112
１１．参考文献一覧
1.
Zeiser R. Prevention of graft-versus-host disease. UpToDate. 2022.
2.
Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with
cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation
for leukemia. N Engl J Med 1986;314(12):729-35.
3.
Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN
working group recommendations for a standardized practice. Bone Marrow Transplant
2014;49(2):168-73.
4.
Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease
after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2020;7(2):e157-67.
5.
Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host
disease after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2024;11(2):e147-59.
6.
Irle C, Deeg HJ, Buckner CD, et al. Marrow transplantation for leukemia following fractionated
total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res
1985;9(10):1255-61.
7.
Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia:
a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host
disease. Blood 1985;66(3):698-702.
8.
Ringdén O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing use of cyclosporin
and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients
with haematological malignancies. Bone Marrow Transplant 1986;1(1):41-51.
9.
Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia:
methotrexate alone compared with a combination of methotrexate and cyclosporine for
prevention of acute graft-versus-host disease. Blood 1986;68(1):119-25.
10. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease
prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled
trials. Blood 1988;71(2):293-8.
11. Bäckman L, Ringdén O, Tollemar J, et al. An increased risk of relapse in cyclosporin-treated
compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone
Marrow Transplant 1988;3(5):463-71.
12. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy
in patients with advanced hematologic neoplasms. N Engl J Med 1989;320(13):828-34.
13. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for
28
要望番号；IV-112
１１．参考文献一覧
1.
Zeiser R. Prevention of graft-versus-host disease. UpToDate. 2022.
2.
Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with
cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation
for leukemia. N Engl J Med 1986;314(12):729-35.
3.
Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN
working group recommendations for a standardized practice. Bone Marrow Transplant
2014;49(2):168-73.
4.
Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease
after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2020;7(2):e157-67.
5.
Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host
disease after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2024;11(2):e147-59.
6.
Irle C, Deeg HJ, Buckner CD, et al. Marrow transplantation for leukemia following fractionated
total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res
1985;9(10):1255-61.
7.
Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia:
a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host
disease. Blood 1985;66(3):698-702.
8.
Ringdén O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing use of cyclosporin
and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients
with haematological malignancies. Bone Marrow Transplant 1986;1(1):41-51.
9.
Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia:
methotrexate alone compared with a combination of methotrexate and cyclosporine for
prevention of acute graft-versus-host disease. Blood 1986;68(1):119-25.
10. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease
prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled
trials. Blood 1988;71(2):293-8.
11. Bäckman L, Ringdén O, Tollemar J, et al. An increased risk of relapse in cyclosporin-treated
compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone
Marrow Transplant 1988;3(5):463-71.
12. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy
in patients with advanced hematologic neoplasms. N Engl J Med 1989;320(13):828-34.
13. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for
28